Evidence map›Paper›PMID 37323813›Full record

ArticleCase reports in hematology2023

Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib.

Vanessa Innao, Rosalba Donatella Calogero, Fabrizio Lo Presti, Ugo Consoli

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vanessa InnaoU.O.C di Ematologia, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, ARNAS, Garibaldi di Catania, Catania, Italy.ORCID https://orcid.org/0000-0001-7596-1912
Rosalba Donatella CalogeroU.O.C di Ematologia, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, ARNAS, Garibaldi di Catania, Catania, Italy.
Fabrizio Lo PrestiU.O.C di Ematologia, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, ARNAS, Garibaldi di Catania, Catania, Italy.
Ugo ConsoliU.O.C di Ematologia, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, ARNAS, Garibaldi di Catania, Catania, Italy.ORCID https://orcid.org/0009-0002-0249-3411
Azienda di Rilievo Nazionale ed Alta Specializzazione · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune thrombocytopenia (ITP) is immune-mediated platelet loss due to increased destruction and insufficient production. Treatment guidelines provide for first-line steroid-based therapies followed by thrombopoietin receptor agonists (TPO-RAs) and fostamatinib for chronic ITP. Fostamatinib demonstrated efficacy in phase 3 FIT trials (FIT1 and FIT2) mainly in second-line therapy resulting in the maintenance of stable platelet values. Here, we describe two patients with extremely heterogeneous characteristics that responded to fostamatinib after two and nine previous treatments. Responses were complete with stable platelet counts ≥50,000/

Identifiers

PMID37323813
PMCPMC10266907
OpenAlexW4379744428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.